B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran

B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran Publisher Pubmed

Safavi F¹ ; Nourbakhsh B² ; Azimi AR³

Show Affiliations

1. National Institutes of Neurological Disorders and Stroke, NIH, MD, United States
2. Department of Neurology, Johns Hopkins University, MD, United States
3. MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Multiple Sclerosis and Related Disorders Published:2020

Abstract

Objective: To determine whether the course of COVID-19 is more severe in patients with MS and if MS disease-modifying treatments (DMTs) affect the risk of contracting the disease. Methods: In a cross-sectional survey, data were collected by sending a questionnaire to 2000 patients with a demyelinating disease through an online portal system. Collected data included the current MS DMT and patient-reported disability level, history of recent sick contact, recent fever, respiratory symptoms, diagnosis with COVID-19, and the disposition after the diagnosis. We defined a COVID-19-suspect group as patients having fever and cough or fever and shortness of breath, or a presumptive diagnosis based on suggestive chest computed tomography. We calculated the proportion of COVID-19-suspect patients and compared their demographics, clinical characteristics, and DMT categories with the rest of survey-responders, using univariable and multivariable models. Results: Out of 712 patients, 34 (4.8%) fulfilled our criteria for being in the COVID-19-suspect group. Only two patients required hospitalization. No patient required intensive care. In a multivariable model, disease duration (p-value=0.017), DMT category (p-value=0.030), and history of sick contact (p-values<0.001) were associated with the risk of being in the COVID-19-suspect group. Being on B-cell depleting antibodies (as compared to non-cell depleting, non-cell trafficking inhibitor DMTs) was associated with a 2.6-fold increase in the risk of being in the COVID-19-suspect group. (RR: 3.55, 95%CI: 1.45, 8.68, p-value=0.005). Conclusions: The course of infection in patients with MS suspected of having COVID-19 was mild to moderate, and all patients had a full recovery. B-cell depleting antibodies may increase the susceptibility to contracting COVID-19. © 2020 Elsevier B.V.

Related Docs

View other Related Docs

1. Vitamin D and Covid-19: From Potential Therapeutic Effects to Unanswered Questions, Reviews in Medical Virology (2021)

2. The Role of Mucosal Immunity and Recombinant Probiotics in Sars-Cov2 Vaccine Development, Probiotics and Antimicrobial Proteins (2021)

3. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)

4. Naringenin, a Flavanone With Antiviral and Anti-Inflammatory Effects: A Promising Treatment Strategy Against Covid-19, Phytotherapy Research (2020)

5. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)

6. Immunomodulatory-Based Therapy As a Potential Promising Treatment Strategy Against Severe Covid-19 Patients: A Systematic Review, International Immunopharmacology (2020)

7. Th17 and Treg Cells Function in Sars-Cov2 Patients Compared With Healthy Controls, Journal of Cellular Physiology (2021)

8. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (12)

Mohammad Ali Sahraian (8)

Style	Citing Format
MLA	Safavi F, Nourbakhsh B, Azimi AR. "B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran." Multiple Sclerosis and Related Disorders, vol. 43, no. , 2020, pp. -.
APA	Safavi F, Nourbakhsh B, Azimi AR (2020). B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran. Multiple Sclerosis and Related Disorders, 43(), -.
Chicago	Safavi F, Nourbakhsh B, Azimi AR. "B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran." Multiple Sclerosis and Related Disorders 43, no. (2020): -.
Harvard	Safavi F, Nourbakhsh B, Azimi AR (2020) 'B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran', Multiple Sclerosis and Related Disorders, 43(), pp. -.
Vancouver	Safavi F, Nourbakhsh B, Azimi AR. B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran. Multiple Sclerosis and Related Disorders. 2020;43():-.
BibTex	@article{ author = {Safavi F and Nourbakhsh B and Azimi AR}, title = {B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran}, journal = {Multiple Sclerosis and Related Disorders}, volume = {43}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Safavi F AU - Nourbakhsh B AU - Azimi AR TI - B-Cell Depleting Therapies May Affect Susceptibility to Acute Respiratory Illness Among Patients With Multiple Sclerosis During the Early Covid-19 Epidemic in Iran JO - Multiple Sclerosis and Related Disorders VL - 43 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract